Dr. Eric Donnenfeld: April 23, 2019



Dr. Eric Donnenfeld

Internationally recognized expert and pioneer in refractive, cornea and cataract surgery anone of the leading refractivand cataract surgeons in the United States 

According to the American Academy of Ophthalmology, approximately 24.5 million Americans have cataracts1, a leading cause of vision impairment in the United States. Over 4 million cataract surgeries are performed each year2, making it the most common surgery performed in the U.S. While cataract surgery remains the most effective way to help restore vision for those with cataracts, treatment of surgically induced inflammation remains an important component of patient care.


Did You Know?

Β· Cataract prevalence in the United States is expected to double by 20501

Β· The average age of cataract surgery patients is 733

Β· Post-operative eye drop regimens typically require multiple therapies

Dr. Donnenfeld is available for interviews via satellite to discuss innovation in the treatment of post-operative inflammation following cataract surgery and what this means for post-surgical patient care. He will discuss some of the biggest challenges for post-surgical patient care and share his insights on the latest technological advances that will affect the future of drug delivery to the eye.



EriDDonnenfeldMD, is ainternationally recognized expert and pioneer in refractive, cornea and cataract surgery anone of the leading refractivand cataract surgeons in the United States. Dr. Donnenfeld graduated magna cum laude from Dartmouth College in 1977 and first in his class at Dartmouth MedicaSchooin 1980. He was Chief Resident at Manhattan Eye, Eaand Throat Hospitaand completed a Cornea and Refractive Fellowship at WillEye Hospital in Philadelphia, PA. Dr. Donnenfeld is on thBoard of Overseers of Dartmouth MedicaSchool and a ClinicaProfessor of Ophthalmology at New York University MedicaCenter. Dr. Donnenfeld wathe President of the American Society of Cataract and Refractive Surgery from 2013-2014Dr. Donnenfeld is the Chief Medical Editor of Cataract and Refractive Surgery Today. He is on the Executive Boards of ASCRS and ACOS and is member of the Refractive Committee of ASCRS and Cornea section of OculaSurgery News. Dr. Donnenfelis National Medical Director of TLC Laser Eye Centers anSurgical Director othe Lions Eye Bank for LonIsland. He is past president othe Ocular Microbiology and Immunology Group. LocallyDr. Donnenfeld has also serveas a board member of the Nassau Academy of Medicine, thAmerican College of Surgeons Long Island Chapteand the Nassau Surgical Society, and is a past president of the Nassau Surgical Society, where his the youngest person to ever receive their Lifetime Achievement AwardDr. Donnenfeld has served as Resident Instructoat Manhattan Eye, Ear and Throat Hospital and as Program Director at North Shore University Hospital.  Dr. Donnenfeld has designed and patentesix instruments for refractive surgery useHe has authored more than 180 papers on cornea, external disease, cataracand refractive surgery, 500 scientific articles, and 40 books and book chapters on a range of subjects pertaining to corneal transplants, cataract care and laser vision correction. Dr. Donnenfeld is on the editorial board of nine journals and has participated in over 40 FDA studies.  He is onof the first five people in the world to perform both lasevision correction and laser cataract surgery. Dr. Donnenfelis a Fellow of the American Academy of Ophthalmology and has received itHonor Award, Senior Honor Award, Life Achievement Honor Award anSecretariat Award. Dr. Donnenfeld has performed laser visiocorrection oover 70,000 patients and more than 1,000 eye doctors and their families. ThJournal of Cataract & Refractive Surgery has named Dr. Donnenfelas onof the Top 50 Most InfluentiaOphthalmologists ithe United StatesDr. Donnenfeld is a foundinpartner in Ophthalmic Consultants of Long Island, OCLI, which consists of 30 eye doctors and surgeons representing broad spectrum of specialties iophthalmology and optometry with nine.

Produced for: EyePoint Pharmaceuticals

Speak Your Mind